Journal of Clinical Oncology
Articles in this Issue
First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).
3111 Background: The Hippo pathway is implicated in multiple human cancers including mesothelioma and epithelioid hemangio...
Comparison of efficacy between 2 and 3 cycles of neoadjuvant immunotherapy combined with chemotherapy for LA HNSCC.
6101 Background: To compare efficacy, safety and long-term survival of 2 vs 3 cycles of neoadjuvant PD-1 inhibitor plus ch...
CAR T-cell detection and clonality assessment in immune effector cell–associated enterocolitis following ciltacabtagene autoleucel.
7537 Background: Ciltacabtagene autoleucel (cilta-cel) is an FDA approved chimeric antigen receptor (CAR) T cell therapy f...
Severe immune-related adverse events in the neoadjuvant and adjuvant setting.
e24184 Background: Immune checkpoint inhibitors (ICIs) are increasingly used in early-stage cancers in the peri-operative...
Patient characteristics, treatment patterns, social determinants of health, and safety in patients prescribed nivolumab and hyaluronidase-nvhy by early adopters.
1530 Background: Subcutaneous (SC) nivolumab and hyaluronidase-nvhy (nivo + hyal) is approved for administration across mo...
Synovial sarcoma misdiagnosis and potential utility of NGS testing patient identification for autologous T cell therapy: Retrospective analysis of Tempus database.
11543 Background: Metastatic synovial sarcoma (SS) is commonly treated with anthracycline and other chemotherapy with poor...
Trends in mortalities due to pneumonitis in esophageal cancer in the United States, 1999-2020: A population-based analysis.
e16146 Background: Esophageal cancer is an aggressive malignancy with a high global burden and poor survival. In 2020, it...
Association between survival outcomes in patients with multiple myeloma and treatment facility volume.
7529 Background: Oncology research previously demonstrated a volume-outcome relationship, where patients treated at health...
Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).
TPS7103 Background: Despite recent advancements in NHL therapies, many patients experience disease progression or relapse....
CD56 and P16 expression in the differential diagnosis of papillary thyroid carcinoma and benign follicular neoplasms.
e18057 Background: The differential diagnosis between papillary carcinoma and follicular thyroid neoplasia is sometimes ve...
Actionable genomic alterations and outcomes in lung squamous and adenosquamous cell carcinoma.
8632 Background: Actionable genomic alterations (AGA) are uncommon in lung squamous/adenosquamous carcinoma (LUSC/LUASC) a...
Evolution of symptom burden across prostate cancer disease states in the EHR-facilitated Cancer Symptom Control (E2C2) trial.
e23276 Background: More than 50,000 patients with cancers of all stages were enrolled in the E2C2 trial, which captured pa...
Impact of IBI3017, an innovative bispecific anti-Trop2 and B7H3 antibody-drug conjugate, on anti-tumor efficacy in a wide range of tumors.
e20508 Background: Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combini...
Comprehensive epigenomic profiling of plasma for non-invasive detection of MET activation to uncover MET-associated biology in patients with <i>EGFR</i> -mutated advanced NSCLC and progression on osimertinib.
8642 Background: Genomic overexpression or amplification of MET is an established...
Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.
4546 Background: Dual immune checkpoint inhibitor (IO-IO) and immune checkpoint inhibitor plus VEGF receptor tyrosine kina...
CancerTrialsBR: An open-access, collaborative platform to improve visibility and access to cancer clinical trials in Brazil.
1546 Background: Lack of timely and understandable information is a major barrier for cancer trials recruitment, particula...
The influence of immune checkpoint inhibitors on treatment results in cancer patients: Real-world evidence from a single institution in a low-middle-income country.
e23370 Background: Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity by modulating specific immune pathways....
Assessment of efficacy of hereditary cancer didactic training program for advanced practice providers in the community oncology setting.
e13546 Background: Many professional organizations, including ASCO, recommend evaluation of personal and family history of...
Real-world experience with inotuzumab ozogamicin in high-risk and R/R B-cell acute lymphoblastic leukemia.
e18507 Background: Inotuzumab ozogamicin (InO) is an effective CD22-directed antibody–drug conjugate for relapsed/refracto...
COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in <i>EGFR</i> -mutated advanced NSCLC: Interim results.
8614 Background: In MARIPOSA-2, intravenous ami + carboplatin-pemetrexed chemo significantly prolonged progression-free su...
A research-based initiative to coordinate care for patients with basal cell carcinoma and cutaneous squamous cell carcinoma.
e21004 Background: Community teams managing basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) report...
FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).
TPS5644 Background: Folate receptor alpha (FRα) is overexpressed in ovarian cancer and is a validated therapeutic target....
Efficacy and safety of rivaroxaban compared with LMWH in patients with cancer-associated thrombosis: A systematic review and meta-analysis of randomized controlled trials.
e15136 Background: The optimal anticoagulation strategy for managing cancer-associated thrombosis (CAT) remains uncertain....
Long term trends in Hodgkin's lymphoma incidence in the United States and Puerto Rico, 1999 to 2022.
e19043 Background: Hodgkin lymphoma (HL) is a highly curable malignancy; however, population-level incidence trends vary a...
Investigating quality of life and decision regret in patients undergoing laryngectomy procedure.
e23267 Background: Total laryngectomy is a surgical procedure for head and neck cancers that involves the removal of the l...